June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular edema (DME): the RESTORE study
Author Affiliations & Notes
  • Paul Mitchell
    Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Victor Chong
    Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Footnotes
    Commercial Relationships Paul Mitchell, Novartis (R), Bayer (R); Victor Chong, Novartis (C), Bayer (C), Allergan (C), Pfizer (F), Novartis (F), Alimera Science (C), Quantel (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Paul Mitchell, Victor Chong, RESTORE Study Group; Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular edema (DME): the RESTORE study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Predicting response to therapy is an important aspect of patient care. We sought to identify baseline factors that predicted long-term visual outcomes in patients with visual impairment due to DME who received ranibizumab in the RESTORE core and extension study.

Methods: RESTORE was a 12-month, phase III randomised, controlled, clinical trial that compared laser photocoagulation, ranibizumab 0.5mg, and ranibizumab 0.5mg combined with laser photocoagulation. Patients completing RESTORE were eligible for enrollment into the 24 month RESTORE extension study. Ranibizumab was administered as three monthly initiating doses, followed by as-needed dosing similar to the EU product label. At Month 12, all patients were eligible for ranibizumab 0.5mg as-needed. Change from baseline in best-corrected visual acuity (BCVA) at 36 months/LOCF was analysed using multivariate linear regression adjusting for baseline characteristics.

Results: In both ranibizumab- and laser only-initially treated patients (n=166 and n=74 respectively), the baseline characteristic most strongly correlated (Inversely) with change in BCVA was baseline VA (p=0.0002 and p<0.0001 respectively). Older age, duration of both diabetes and DME were also significantly correlated with 36-month BCVA in ranibizumab-treated patients only (p=0.045, 0.013, and 0.045 respectively). Shorter duration periods for diabetes and also for DME were associated with better clinical responses to ranibizumab treatment. In patients initially treated with laser, but not in patients commenced on either of the ranibizumab regimens, baseline central retinal thickness correlated positively with change in BCVA (p=0.0063).

Conclusions: Baseline BCVA was a strong predictor of BCVA changes over 36 months, so that patients with poorer VA achieved greater gains than those with better baseline vision. Other correlates varied by treatment modality, consistent with differing modes of action between ranibizumab and laser photocoagulation. Better responses in patients with more recently diagnosed DME highlights the need for prompt therapy.

Keywords: 499 diabetic retinopathy • 585 macula/fovea • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×